News
Hims & Hers, LifeMD stocks skyrocket after inking deal with Novo Nordisk to sell Wegovy
Pharma giant Novo Nordisk is partnering with telehealth companies to expand access to its blockbuster weight loss drug Wegovy. | Novo Nordisk and Hims & Hers struck a truce after sparring over compounded versions of the pharma giant's branded GLP-1 drugs.
Hims & Hers Health (NYSE: HIMS) stock surged 23% on Tuesday, April 29, after Novo Nordisk announced plans to offer popular ...
While there's still plenty of work to be done, Hims is one of many such companies that's helping to expand healthcare options, by opening the conversation around men's health, in particular.
Inc. (HIMS), which connects consumers to healthcare professionals, is at a crossroads. With sales of a significant drug set to fade, commercial innovations are needed to maintain the company’s ...
“If HIMS is able to generate commercial success for liraglutide, it would represent a significant milestone and validate the strength of HIMS’ brand, in our view.” ...
Hims is a telehealth platform for men that offers virtual care for various health concerns. The platform addresses issues such as hair loss, sexual health, weight management, skincare and mental ...
Novo Nordisk appears to be letting compounded GLP-1 bygones be bygones—at least, in one respect. | Novo Nordisk appears to be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback